Navigation Links
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Date:3/9/2009

Overall, the two studies enrolled and randomized a total of 2264 treatment-naive patients.

The dose modification in January 2008 was recommended by the independent Data Monitoring Committee (DMC) based upon an interim analysis that serious pulmonary adverse events appeared to be higher in the 1200-mcg albinterferon alfa-2b treatment group.

  • Across the two Phase 3 trials, which have now been completed, rates of serious respiratory, thoracic or mediastinal disorders were: 0.7% (5/755) for 900-mcg albinterferon alfa-2b; 1.5% (11/750) for the group originally randomized to receive 1200-mcg albinterferon alfa-2b, and 0.0% (0/750) for peginterferon alfa-2a.
  • Central blinded review of chest X-rays recommended by the DMC for patients participating in the two Phase 3 trials demonstrated that the overall rates of significant interstitial findings were comparable in all three treatment groups: 4.3% (20/469) in patients randomized to receive 900-mcg albinterferon alfa-2b; 4.8% (22/454) in patients originally randomized to receive 1200-mcg albinterferon alfa-2b; and 4.5% (22/484) in patients randomized to receive 180-mcg peginterferon alfa-2a.

The incidence of fatality in the albinterferon alfa-2b Phase 3 trials was rare. All-cause mortality rates were: 0.13% (1/756) in patients randomized to receive 900-mcg albinterferon alfa-2b every two weeks; 0.53% (4/751) in patients originally randomized to receive 1200-mcg albinterferon alfa-2b every two weeks; and 0.27% (2/751) in patients randomized to receive 180-mcg peginterferon alfa-2a once-weekly.

Across the two Phase 3 trials, the overall percentage of patients who had a serious and/or severe adverse event or discontinued due to an adverse event was comparable in all dose groups: 23.2% (175/755) in patients randomized to receive 900-mcg albinterferon alfa-2b; 26.0% (195/750) in patients randomized to r
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Drug Development Program Started Based on CAP(R) Human Cell Line
2. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
3. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
4. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
9. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
10. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
11. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
(Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
... Pa., Dec. 7, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... to fight cancers and infectious diseases, announced today that ... shares of its common stock and warrants to purchase ... which included the partial exercise of the underwriter,s overallotment ...
... -- The November 14, 2011, edition of ... Presence (VIP) as 4 stars ("would take it on ... Experiment (AEWE),s Spiral G at Fort Benning, GA, culminating ... and November 2011.  "It was a pleasure ...
Cached Medicine Technology:Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 2Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 3Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing 4VIPAAR's VIP Earns 4-star Technology Rating at AEWE's Spiral G 2
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ( WEDI ... efficiencies in healthcare information exchange, announced the release of its findings from its June ... (HHS) Secretary, WEDI shared survey results and recommendations , strongly encouraging ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... to contract research organisations (CROs) for a slew of benefits, allowing them to ... and operations, boost quality with cost-effective utilisation of resources, get access to innovation ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bodybuilding.com, ... of nutritional supplements, has officially opened the polls for their eleventh annual ... following categories:, ,     Brand of the Year (BPI Sports) ...
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing ... from her grandmother’s side at a young age, Nasreen Zereshki was extremely eager to ... to share her cookbook Recipes from My Persian Kitchen with the world. , Since ...
Breaking Medicine News(10 mins):Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2
... South Korea, July 20 HepaHope Korea ... owned subsidiary, VASKA, a Berkeley-based producer of green, botanically-based ... successfully turned the first major commercial laundry plant in the United ... South San Francisco is the largest privately owned commercial laundry on ...
... , CARY, N.C., July 20 ... company focused on acquiring, developing and commercializing products primarily for ... Executive Vice President, Finance, and Chief Financial Officer, has been ... in the Small Public Business category. Award recipients were ...
... CARLSBAD, Calif., July 20 SynergEyes, Inc., ... a new advanced lens design for keratoconus patients. ClearKone(TM) ... the best features of the hybrid platform, providing superior ... design is optimized to vault the predominant irregularities of ...
... , BANNOCKBURN, Ill., July 20 Heart disease is ... it,s often not until the untimely passing of a celebrity from a ... the issue is brought to the forefront of Americans, health and wellness ... a recent survey(2) uncovered that only 14 percent of people would be ...
... Population older than 65 could reach 1.3 billion by 2040 ... people who are age 65 and older will double from ... 2040, says a new U.S. Census Bureau study. , The ... last year to 1.3 billion in 30 years. The unprecedented ...
... PLAINS, N.Y. and CAMBRIDGE, Mass., July 20 The ... partnership to accelerate LLS,s pipeline of research projects entering late pre-clinical ... will begin with a selection of ten small molecule candidates, discovered ... of advancing into clinical trials in the shortest period of time. ...
Cached Medicine News:Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Cornerstone Therapeutics' David Price Named 2009 Chief Financial Officer of the Year by the Triangle Business Journal 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 2Health News:SynergEyes, Inc. Launches New Hybrid Lens Design for Keratoconus Patients 3Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 3Health News:Elder Boom Will Be Felt Worldwide 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 3
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,412-7) or contact custom...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... features: Eppendorf "pipette/tip" system ensures utmost ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: